Literature DB >> 16301263

The use of small-dose theophylline for the treatment of bradycardia in patients with spinal cord injury.

Sebastian Schulz-Stübner1.   

Abstract

Small-dose theophylline can be a useful alternative in the treatment of bradycardia in patients with spinal cord injury. In this series of three cases, I describe its successful use for this indication. In one case, initiation of theophylline treatment also increased respiratory drive and minute ventilation. A possible mechanism is that theophylline increases the force of contraction of diaphragmatic muscles because of enhancement of calcium uptake through an adenosine-mediated channel. The antibradycardiac effect is probably mediated through one or more different molecular mechanisms, which seem to be mediated by inhibition of phosphodiesterase 3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301263     DOI: 10.1213/01.ANE.0000184203.52747.7D

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

1.  Theophylline for bradycardia secondary to cervical spinal cord injury.

Authors:  Farid Sadaka; Soophia Khan Naydenov; John J Ponzillo
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

2.  Aminophylline for the treatment of symptomatic bradycardia and asystole secondary to cervical spine injury.

Authors:  Kyle A Weant; Michaux Kilpatrick; Sivakumar Jaikumar
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

3.  Management of Hypotension and Bradycardia Caused By Spinal Cord Injury. The Usefulness of Midodrine and Methylxanthines.

Authors:  Mojtaba Mojtahedzadeh; Hamidreza Taghvaye-Masoumi; Atabak Najafi; Mehrnoush Dianatkhah; Hamidreza Sharifnia; Maryam Shahrokhi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

Review 4.  Pharmacologic Approach to Sinoatrial Node Dysfunction.

Authors:  Pietro Mesirca; Vadim V Fedorov; Thomas J Hund; Angelo G Torrente; Isabelle Bidaud; Peter J Mohler; Matteo E Mangoni
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-10-05       Impact factor: 13.820

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.